SCHEMBL5376111

SCHEMBL5376111

CC(=O)N1CCC(N2CCCC(N)C2=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.42
EPHX2 P34913 2/20 0.37
EPHX1 P07099 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 1/20 0.37
APEX1 P27695 1/20 0.37
BACE1 P56817 1/20 0.36
BMPR1A P36894 1/20 0.35
ACVRL1 P37023 1/20 0.35
ACVR1 Q04771 1/20 0.35
DPP4 P27487 2/20 0.35
HTR2A P28223 1/20 0.34
TMEM97 Q5BJF2 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
QDPR P09417 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
MAP3K7 O43318 1/20 0.33
TAB1 Q15750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2598560 0.86 CYP3A4 (0.38) CYP3A4TSHRTDP1MAPTAPEX1
SCHEMBL5376108 0.82 PARP1 (0.43) PARP1EPHX2EPHX1BACE1BMPR1A
SCHEMBL5368531 0.81 ITGB3 (0.37) CYP3A4TSHRTDP1MAPTAPEX1
SCHEMBL794429 0.80 FPR2 (0.48) EPHX1MAPTBACE1
SCHEMBL794430 0.80 FPR2 (0.48) EPHX1MAPTBACE1
SCHEMBL4656939 0.80 CYP3A4 (0.37) CYP3A4TSHRTDP1MAPTAPEX1
SCHEMBL31228098 0.79 CYP3A4 (0.42) CYP3A4TSHRTDP1MAPTAPEX1
SCHEMBL25873180 0.79 CYP3A4 (0.42) CYP3A4TSHRTDP1MAPTAPEX1
SCHEMBL4626141 0.76 PARP1 (0.40) PARP1CYP3A4TSHRTDP1MAPT
SCHEMBL4656280 0.76 PARP2 (0.40) CYP3A4TSHRTDP1MAPTAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7169795-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-01-30 US claimed
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-05-05 US claimed
US-7312218-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB CO. (US) 2007-12-25 US disclosed
US-20070099922-A1 SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS HAN WEI 2007-05-03 US disclosed
US-7169795-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-01-30 US disclosed
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099922-A1 SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS TFPI, F12, F5 PARP1 1406/4885EPHX2 3811/4885EPHX1 3775/4885
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors TFPI, F12, F5 PARP1 1406/4885EPHX2 3811/4885EPHX1 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.